Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
常见问题
Defiance AI & Power Infrastructure UCITS 今天的股价是多少?▼
AIPO.SW 当前价格为 CHF5.51 CHF,在过去 24 小时内下跌了 -2.31%。在图表上更密切关注 Defiance AI & Power Infrastructure UCITS 股票的表现。
Defiance AI & Power Infrastructure UCITS 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 SIX Swiss Exchange 交易所,Defiance AI & Power Infrastructure UCITS 的股票以代码 AIPO.SW 进行交易。
Defiance AI & Power Infrastructure UCITS 的市值是多少?▼
今天 Defiance AI & Power Infrastructure UCITS 的市值为 115.8M
Defiance AI & Power Infrastructure UCITS 下一次财报日期是什么时候?▼
Defiance AI & Power Infrastructure UCITS 将于 2026年11月16日 发布下一次财报。
Defiance AI & Power Infrastructure UCITS 上一季度的财报怎么样?▼
AIPO.SW 上季度财报为每股 -0.74 CHF,预估为 -0.11 CHF,带来 -603.79% 的意外。下季度预估财报为每股 不适用 CHF。
Defiance AI & Power Infrastructure UCITS 有多少名员工?▼
截至2026年11月7日,公司共有5名员工。
Defiance AI & Power Infrastructure UCITS 属于哪个行业?▼
Defiance AI & Power Infrastructure UCITS从事于健康与养生行业。
Defiance AI & Power Infrastructure UCITS 何时完成拆股?▼
Defiance AI & Power Infrastructure UCITS 最近没有进行任何拆股。
Defiance AI & Power Infrastructure UCITS 的总部在哪里?▼
Defiance AI & Power Infrastructure UCITS 的总部位于 美国 的 PRINCETON。